HURA TuHURA Biosciences Inc.

$HURA good volume though we’ve seen these kind moves before only for a violent drop after. No news aside from some patents makes it a pure pump for now.

$HURA Two recent U.S. patents expand protection for TBS-2025, our VISTA-inhibiting antibody, and specified uses of DOR antagonists in cancer. Our preclinical ADC approach is designed to link a DOR inhibitor to our VISTA-inhibiting antibody. TBS-2025 also has FDA IND clearance for a Phase 1b study in relapsed or refractory AML with mutated NPM1. The patents help protect potential commercial value across these development paths, including opportunities for future collaboration.

$HURA given that the p3 is running behind, will they take vista into the clinic? Vista deal with Janssen? They are not paying Tendler $1,250 per hour for nothing. Mono first then a deal? We will see soon enough.

$HURA Our new U.S. patent expands protection for TBS-2025, our VISTA-inhibiting antibody, across specified molecular modifications and treatment uses. This strengthens the IP behind the program and helps protect its potential commercial value as development advances.

$HURA The potential applications of our DOR technology extend beyond the ADC platform we are developing. Our newly issued patent covers specified uses of DOR antagonists in cancer and discloses applications involving cellular immunotherapies, including CAR-T, Treg and TIL therapies. For a therapeutic technology, patent protection is part of building a path toward potential commercialization. This patent has a term through 2043, before any patent-term extension, protecting specified uses of the technology as preclinical development progresses. The disclosed cellular-therapy applications also show how the same technology could be explored across additional treatment approaches.

$HURA pump and dump cycle almost complete, back to where we were weeks back... same pattern.. follow official pr, always drops after that

$HURA I see no way that today’s news is anything but positive. They showed at a minimum that ifx can be safely administered to deep seated tumors. That alone allows for the possibility that additional tumor types beyond mcc might be treatable. 4 pts dosed is not a lot but having 3/3 responders so far also cannot be a bad thing.